Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-$5.33M-103%
Cytokinetics logo
CytokineticsCYTK
-$200.98M-47.7%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-$121.47M-5.5%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$34.48M-46.1%
Scholar Rock logo
Scholar RockSRRK
-$109.45M+0.6%
Wave Life Sciences logo
Wave Life SciencesWVE
-$69.27M-37.4%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.73B+245%
Enterprise value$4.7B+253%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
Line itemThree months ended March 31, 2026Three months ended March 31, 2025
Interest income5,1025,161
Total other income5,1025,161
Net loss(49,013)(40,798)
Other comprehensive income (loss):
Unrealized loss on available-for-sale securities, net(929)(19)
Total comprehensive loss$(49,942)$(40,817)
Net loss per share, basic and diluted$(0.46)$(0.43)
Weighted-average shares outstanding, basic and diluted107,116,70995,130,053

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Edgewise Therapeutics, Inc. (EWTX) reported comprehensive income (loss), net of tax, attributable to parent of -$49.94M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 22.4% year-over-year, from -$40.82M to -$49.94M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 40.2% compound annual growth rate (CAGR), from -$43.33M to -$167.54M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items like unrealized gains or losses on investments. It provides a comprehensive view of the company's total financial performance beyond the standard net income figure. This is a critical measure for assessing the overall impact of both operational results and market-driven valuation changes on shareholder equity.

Ask your AI about Edgewise Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude